# Preimplantation Genetic Testing Market

> Preimplantation Genetic Testing Market Research Report: Size, Share, Trend Analysis By Applications (Diagnostic Testing, Carrier Screening, Embryo Selection), By Technique (Polymerase Chain Reaction, Next Generation Sequencing, Fluorescence In Situ Hybridization, Single Nucleotide Polymorphism), By End Use (Fertility Clinics, Research Laboratories, Hospitals), By Client Type (Individuals, Healthcare Providers, Healthcare Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 9.8%
- **2025:** USD 954.0 Million
- **2035:** USD 2,429.9 Million
- **Key Players:** CooperSurgical (CooperGenomics), Illumina, Inc., Thermo Fisher Scientific, Vitrolife Group (Igenomix), Natera, Inc., Labcorp, Quest Diagnostics, Revvity (formerly PerkinElmer)

**Report ID:** MRFR/HC/6649-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** September 10, 2026

**URL:** https://www.marketresearchfuture.com/reports/preimplantation-genetic-testing-market-8121

---

## Market Summary

## Preimplantation Genetic Testing Market Summary

The Preimplantation [Genetic Testing](https://www.marketresearchfuture.com/reports/genetic-testing-market-2009) Market reached USD 954.0 Million in 2025 and opens the forecast window at USD 1,047.5 Million in 2026, climbing to USD 2,429.9 Million by 2035 at a 9.8% CAGR. Two policy catalysts anchor that trajectory. Executive Order 14216, signed February 2025, directed federal agencies to cut out-of-pocket IVF costs and broaden employer-funded fertility benefits [[3]](https://www.govinfo.gov/content/pkg/DCPD-202500278/pdf/DCPD-202500278.pdf). California's SB 729, effective January 2026, obliges large group plans to fund up to three egg retrievals and unlimited embryo transfers for roughly nine million enrollees [[5]](https://leginfo.legislature.ca.gov/).

Laboratories are retiring fluorescence in situ hybridisation and array comparative genomic hybridisation in favour of high-throughput sequencing. Illumina's January 2025 NovaSeq X refresh cut per-sample reagent cost materially, and its analytics alliance with Tempus AI extended machine-learning scoring into reproductive genomics [[15]](https://investor.illumina.com/)[[19]](https://investors.tempus.com/). CooperSurgical's USD 875 million purchase of Cook Medical's reproductive health division bundled disposables with genomics contracts across chain clinics [[14]](https://investor.coopercos.com/). The Preimplantation Genetic Testing Market is consequently shifting from instrument sales toward recurring consumable and software revenue.

North America commands 38.6% of the Preimplantation Genetic Testing Market, supported by employer benefit design and 25 state coverage mandates [[2]](https://www.who.int/publications)[[6]](https://www.congress.gov/bill/119th-congress/house-bill/3480). Asia-Pacific compounds fastest at 13.7%, propelled by Chinese and Indian clinic build-outs. Europe follows as second-largest at 28.4%, where reimbursement code expansion and cross-border patient flows sustain volume. The next decade rewards vendors who solve turnaround time, not those who simply sequence deeper.

## Key Report Takeaways

### • By Technology

- Next-generation sequencing held 50.8% of the Preimplantation Genetic Testing Market in 2025, displacing legacy karyotyping workflows.
- AI-assisted imaging is the fastest-expanding technology at an 11.6% CAGR through 2035
- [Polymerase chain reaction](https://www.marketresearchfuture.com/reports/polymerase-chain-reaction-market-19212) platforms generated USD 172.5 Million in 2025, retaining relevance in single-gene work.

### • By End User

- Fertility clinics accounted for 63.0% of the Preimplantation Genetic Testing Market in 2025

### • By Product & Services

- Consumables and reagents delivered USD 546.6 Million in 2025, the largest product pool
- Software and services advance at a 12.2% CAGR, the quickest product category

### • By Region

- North America led the Preimplantation Genetic Testing Market with a 38.6% share in 2025
- Asia-Pacific posts the highest regional CAGR at 13.7% to 2035
- Europe generated USD 270.9 Million in 2025 across eight tracked country markets

## Market Size and Forecast (2021–2035)

Sizing blends clinic-level cycle counts from national ART registries, vendor consumable shipment data, and reported segment revenue from twelve public filings. Historical values are triangulated against CDC and ESHRE cycle volumes, then reconciled bottom-up using average per-embryo test pricing by region. Forecast years apply cohort-based penetration modelling rather than straight-line extrapolation, which matters because PGT attachment rates plateau in mature payer markets. The Preimplantation Genetic Testing Market figures below are stated in USD Million at 2025 constant prices.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising maternal age at first conception | +2.1 pp | Global; acute in East Asia, Western Europe | Long-term (≥4 yr) | [1][21] |
| Employer and state IVF coverage mandates | +1.8 pp | North America | Short-term (≤2 yr) | [3][5] |
| Sequencing cost decline and lab automation | +1.6 pp | Global | Medium-term (2–4 yr) | [15][16] |
| AI-assisted embryo prioritisation | +1.3 pp | North America, Europe, China | Medium-term (2–4 yr) | [19] |
| Cell-free DNA method validation | +1.1 pp | Asia-Pacific, Southern Europe | Long-term (≥4 yr) | [10][11] |
| Fertility clinic chain consolidation | +0.9 pp | North America, UK, Australia | Short-term (≤2 yr) | [14] |
| European reimbursement code expansion | +0.7 pp | Europe | Medium-term (2–4 yr) | [7][8] |

### Demographic Shift in Maternal Age

Since 2010, the average age at first birth has increased in all OECD countries, and the probability of aneuploidy increases sharply beyond age 35 [[21]](https://www.oecd.org/health/). Chromosome testing is now included in about 60% of US IVF cycles, a penetration rate that was unimaginable ten years ago [[11]](https://www.sciencedirect.com/science/article/pii/S1472648325002846). This driver functions more like a bottom beneath the preimplantation genetic testing market than a cycle since the underlying demographic curve is slow-moving and permanent.

### Coverage Mandates and Employer Benefit Design

Prior to 2025, only one in four US firms provided any kind of fertility benefit [[4]](https://www.whitehouse.gov/). In October 2025, the White House negotiated an 84% discount on common gonadotropins through a direct purchasing channel and established a pre-tax conduit for independent fertility coverage structured like dental or vision insurance [[4]](https://www.whitehouse.gov/). That excepted-benefit designation would be formalized by a tri-agency proposed rule in May 2026 [[23]](https://www.federalregister.gov/). The household budget for the genetic testing add-on is freed up by less expensive medication.

### Sequencing Economics

Reagent cost per embryo has fallen roughly 45% since 2021 as short-read platforms scaled [[15]](https://investor.illumina.com/). Thermo Fisher's July 2023 Ion ReproSeq and Ion AmpliSeq polyploidy kits pushed benchtop sequencing into mid-volume laboratories that previously outsourced entirely [[16]](https://ir.thermofisher.com/). Lower fixed cost changes who can compete, not merely what testing costs.

### Machine Learning in Embryo Selection

Predictive models now approach 88% accuracy for chromosomal normality using time-lapse morphokinetics alone [[19]](https://investors.tempus.com/). Clinics deploy these tools upstream of biopsy to triage which embryos justify testing, raising informative-result rates and trimming per-cycle spend.

## Restraints

## Restraints Impact Analysis

Restraint weightings follow the same directional convention as Section 4 and represent drag on compound growth rather than subtractable percentages. Several restraints are jurisdiction-specific, so global impact is diluted relative to local severity.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Out-of-pocket add-on cost of USD 3,000–6,000 per cycle | −1.9 pp | Global | Short-term (≤2 yr) | [4][13] |
| Clinical-utility disputes and randomised evidence gaps | −1.4 pp | North America, Europe | Medium-term (2–4 yr) | [12] |
| Statutory prohibitions and ethical restrictions | −1.2 pp | Germany, Italy, Gulf states | Long-term (≥4 yr) | [7] |
| Mosaicism interpretation variability | −0.9 pp | Global | Medium-term (2–4 yr) | [9] |
| Embryologist and clinical geneticist shortage | −0.8 pp | Asia-Pacific, Latin America | Long-term (≥4 yr) | [24] |

### Cost Sensitivity Where Coverage Is Absent

Half of the nation is exposed because 25 states and the District of Columbia require some form of fertility coverage [[6]](https://www.congress.gov/bill/119th-congress/house-bill/3480). Mandate figures overestimate actual protection because self-insured firms are completely exempt from state obligations. When a cycle already costs USD 5,000–10,000 before medicine, cash-paying patients frequently refuse testing [[4]](https://www.whitehouse.gov/). The preimplantation genetic testing market's penetration is limited by this price elasticity well below clinical eligibility.

### Contested Clinical Utility

Due to variable live-birth benefits across randomized trials, professional groups have refrained from endorsing aneuploidy testing universally in patients with good prognoses [[12]](https://www.asrm.org/). When they refuse coverage, payers point to this ambiguity. Reimbursement expansion moves one plan at a time rather than by category until a robust multicenter trial answers the question.

### Mosaicism and Reporting Standards

Intermediate copy-number results defy binary classification, and society guidance remains advisory [[9]](https://www.pgdis.org/). Two laboratories can call the same blastocyst differently. That variability erodes clinician confidence and slows adoption in conservative practices.

## Opportunities

## Preimplantation Genetic Testing Market Opportunities

### Non-Invasive Testing at Scale

Biopsy danger and the expertise barrier for embryologists that limits rural clinics are eliminated by spent-culture-medium analysis. When culture techniques are extended to day six, published concordance with trophectoderm biopsies now exceeds meaningful thresholds [[10]](https://academic.oup.com/humrep/article/39/9/1952/7721576)[[11]](https://www.sciencedirect.com/science/article/pii/S1472648325002846). Clinics that have never developed biopsy capabilities will be able to access a validated, closed-loop media-collection kit from vendors.

### Software-Led Business Models

More quickly than any hardware line, analytics and reporting multiply at 12.2%. Subscription [bioinformatics](https://www.marketresearchfuture.com/reports/bioinformatics-market-2265) increases switching costs throughout the preimplantation genetic testing market and transforms one-time capital sales into annuity revenue by charging per informative result rather than per instrument.

### Emerging-Market Clinic Build-Out

India, Vietnam and Indonesia are adding ART capacity faster than testing infrastructure. China's assisted reproduction service planning framework set explicit provincial clinic targets, creating a testing gap that regional laboratories are racing to fill [[24]](http://www.nhc.gov.cn/). Price-tiered reagent kits, not flagship platforms, win these accounts.

### Data Monetisation Through Outcome Registries

Laboratories sitting on linked genomic and live-birth data hold an underexploited asset. De-identified outcome registries licensed to pharmaceutical and device developers create a second revenue line while strengthening the evidence base that payers demand.

### Cross-Border Reimbursement Arbitrage

Expanded European procedure codes let patients in restrictive jurisdictions access testing abroad with partial reimbursement [[7]](https://www.eshre.eu/)[[8]](https://www.hfea.gov.uk/). Laboratories in Spain, Cyprus and the Czech Republic that build multilingual counselling and cross-border billing capability capture disproportionate volume.

## Future Outlook

## Preimplantation Genetic Testing Market Future Outlook

### Algorithmic Triage Becomes Standard of Care

Time-lapse imaging paired with trained models will move from research adjunct to routine gatekeeper. Clinics will test fewer embryos per cycle but test them better, holding revenue roughly flat per patient while improving margin. Vendors selling only sequencing chemistry face compression; those selling the decision layer capture the value [[19]](https://investors.tempus.com/).

### Non-Invasive Methods Reach Clinical Parity

Multicentre validation work concluding through 2027 should settle whether spent-medium analysis matches biopsy reliably enough for primary use [[10]](https://academic.oup.com/humrep/article/39/9/1952/7721576)[[11]](https://www.sciencedirect.com/science/article/pii/S1472648325002846). Should it clear, the addressable clinic base widens sharply because biopsy skill ceases to be a prerequisite. The Preimplantation Genetic Testing Market would then expand into secondary-city practices currently outside reach.

### Payer Consolidation of Fertility Benefits

Standalone fertility coverage structured as an excepted benefit could reshape US demand within three years of finalisation [[23]](https://www.federalregister.gov/). Benefit administrators, not clinics, would then select preferred laboratories — shifting negotiating power toward a handful of national contracts and away from clinic-by-clinic selling.

### Ethical Boundary-Setting on Expanded Screening

Whole-genome embryo sequencing entered commercial availability in January 2024, and polygenic scoring followed [[12]](https://www.asrm.org/). Professional societies have declined endorsement. Expect national regulators in Europe and Australia to legislate boundaries before 2030, which will bifurcate the Preimplantation Genetic Testing Market into a regulated clinical tier and a lightly governed direct-pay tier.

## Segment Insights

## Preimplantation Genetic Testing Market Segmentation

### By Test Type

The Preimplantation Genetic Testing Market divides along clinical indication, and mix varies sharply by region.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Aneuploidy Screening (PGT-A) | 43.5% share | Advanced maternal age caseload |
| Monogenic / Single-Gene Disorders (PGT-M) | USD 236.6 Million | Carrier couples and consanguinity risk |
| Structural Rearrangements (PGT-SR) | USD 135.5 Million | Recurrent pregnancy loss referrals |
| Non-Invasive PGT | 11.0% CAGR | Biopsy-free workflow adoption |
| HLA Typing and Others | USD 42.7 Million | Sibling donor matching |

Aneuploidy work remains the volume engine because it applies to a broad patient population rather than a defined risk group. Monogenic testing carries higher realised pricing — bespoke probe design commands a premium — and grows steadily wherever carrier screening precedes conception. Non-invasive methods are the segment to watch; their growth rate reflects a small base, but the operational argument for eliminating biopsy is strong.

### By Technology

Technology selection in the Preimplantation Genetic Testing Market has consolidated faster than most diagnostics categories.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Next-Generation Sequencing (NGS) | 50.8% share | Resolution and cost per embryo |
| PCR / qPCR | USD 172.5 Million | Single-gene and rapid-result workflows |
| SNP Microarray / aCGH | USD 96.4 Million | Legacy installed base and parental origin |
| FISH | USD 38.2 Million | Low-resource laboratory settings |
| AI-Assisted Imaging | 11.6% CAGR | Pre-biopsy embryo triage |

Sequencing displaced arrays because it detects segmental abnormalities and mosaicism that older platforms missed entirely. Polymerase chain reaction persists rather than fades: for a known familial mutation, targeted amplification returns results faster and cheaper than sequencing a whole genome to answer one question.

### By Product and Service

Revenue composition in the Preimplantation Genetic Testing Market has tilted decisively toward recurring streams.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Instruments and Platforms | USD 248.0 Million | Laboratory capacity additions |
| Consumables and Reagents | 57.3% share | Per-embryo test volume |
| Software and Services | 12.2% CAGR | Reporting, interpretation and registry tools |

The increase in testing infrastructure and laboratory capacity was the main driver of the Instruments and Platforms segment's USD 248.0 million in 2025 revenue. With a 57.3% market share, consumables and reagents led the industry thanks to ongoing laboratory use and recurrent testing volumes per embryo. With a 12.2% CAGR, Software and Services was the segment with the fastest growth, driven by rising demand for registry tools, workflow management, digital reporting, and result interpretation.

### By Application

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Aneuploidy and Maternal Age-Related Risk | 45.9% share | Demographic shift in birth age |
| Inherited Monogenic Disease | USD 218.4 Million | Expanded carrier screening uptake |
| Chromosomal Translocation | 9.4% CAGR | Recurrent loss investigation protocols |
| HLA Typing | USD 42.7 Million | Haematopoietic donor sibling cases |
| Other Applications | 8.6% CAGR | Mitochondrial and research indications |

Due to the demographic change toward later-age pregnancies and the resulting rise in genetic risk assessment, the Aneuploidy and Maternal Age-Related Risk segment held a 45.9% market share in 2025. The fastest-growing segment was chromosomal translocation, which grew at a 9.4% CAGR thanks to an increase in the usage of recurrent pregnancy loss study techniques. In the meantime, HLA Typing reached USD 42.7 million due to hematopoietic donor-sibling cases, while Inherited Monogenic Disease earned USD 218.4 million due to the increasing use of extended carrier screening.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Fertility Clinics | 63.0% share | Integrated IVF and testing workflows |
| Hospitals | USD 133.6 Million | Academic medical centre ART units |
| Diagnostic Laboratories | 10.7% CAGR | Outsourced reference testing contracts |
| Research Institutes | USD 47.7 Million | Method development and validation studies |

Fertility clinics dominate because testing decisions happen at the point of embryo culture, not downstream. Reference laboratories grow faster, though, as smaller clinics conclude that in-house sequencing rarely pays back below roughly 900 annual biopsies.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.6% share | Employer benefit design, chain clinic roll-ups, LDT compliance |
| Europe | USD 270.9 Million | Reimbursement codes, cross-border patient flows |
| Asia-Pacific | 13.7% CAGR (2026–2035) | Clinic capacity build-out, domestic sequencing platforms |
| South America | USD 48.7 Million | Private-pay expansion, urban clinic density |
| Middle East & Africa | 3.7% share | Sovereign health programmes, medical tourism hubs |
| Total | USD 954.0 Million | — |

Regional performance in the Preimplantation Genetic Testing Market tracks payer structure more closely than clinical need. Where testing is bundled into covered benefits, attachment rates exceed 55%; where it is a cash add-on, they fall below 20%.

### North America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 84.1% of region | State mandates and employer excepted-benefit pathway [23] |
| Canada | USD 39.8 Million | Provincial ART funding in Ontario and Quebec |
| Mexico | 11.4% CAGR | Cross-border patient inflow and private clinic growth |

Regulatory attention has sharpened. The FDA's laboratory-developed test framework pulls previously exempt in-house assays toward formal oversight, raising validation costs for smaller laboratories while advantaging scaled operators [[20]](https://www.fda.gov/medical-devices/). Chain consolidation compounds that effect: national groups negotiate single-vendor genomics contracts covering dozens of sites, which is why CooperSurgical's disposables-plus-testing bundle proved commercially durable [[14]](https://investor.coopercos.com/).

### Europe

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 21.4% of region | High cycle volume despite restrictive embryo protection statute |
| UK | USD 51.6 Million | HFEA-regulated add-on transparency ratings [8] |
| France | 16.8% of region | Public ART funding through statutory insurance |
| Italy | USD 27.1 Million | Rising private clinic share |
| Spain | 13.9% of region | Cross-border patient destination |
| Nordic Countries | 9.6% CAGR | Registry-linked outcome research |
| Russia | USD 14.9 Million | Domestic reagent substitution |
| Rest of Europe | 8.2% of region | Cyprus and Czech Republic laboratory clusters |

Britain's regulator publishes an evidence rating for every treatment add-on, and aneuploidy testing carries a cautious grade [[8]](https://www.hfea.gov.uk/). That transparency has trimmed opportunistic upselling while lending credibility to clinically indicated use. Germany's statutory constraints push a meaningful share of demand across borders, concentrating revenue in Spanish and Cypriot laboratories rather than suppressing it outright.

### Asia-Pacific

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 32.7% of region | Provincial ART capacity targets [24] |
| India | 16.9% CAGR | ART Regulation Act clinic formalisation |
| Japan | USD 41.6 Million | 2022 public insurance extension to ART |
| South Korea | 11.2% of region | Municipal fertility subsidies |
| ASEAN | USD 25.4 Million | Medical tourism into Thailand and Malaysia |
| Rest of Asia-Pacific | 10.4% CAGR | Australian and New Zealand chain expansion |

Japan's decision to bring assisted reproduction into public insurance reset unit economics overnight, lifting cycle counts and dragging testing volume with them. China presents the opposite structure: capacity is planned centrally, but genetic testing sits largely outside reimbursement, so domestic vendors compete on price rather than payer access. Indian clinics, newly licensed under national ART legislation, are standardising protocols that previously varied clinic to clinic.

### South America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 54.6% of region | São Paulo and Rio private clinic concentration |
| Argentina | USD 9.7 Million | Statutory fertility coverage law |
| Rest of South America | 9.1% CAGR | Chilean and Colombian urban clinic growth |

Argentina's national fertility coverage statute remains among the most generous in the hemisphere on paper, though currency volatility complicates reagent import and pricing. Brazilian demand skews private-pay and price-sensitive, favouring reference-laboratory outsourcing over in-house sequencing capacity.

### Middle East & Africa

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | USD 9.5 Million | Vision 2030 healthcare investment programme |
| UAE | 24.6% of region | Regional medical tourism hub status |
| South Africa | 8.9% CAGR | Private hospital group ART units |
| Egypt | USD 4.9 Million | High cycle volume at low price points |
| Rest of MEA | 15.3% of region | Qatar and Kuwait sovereign health spending |

Gulf states combine strong consanguinity-driven demand for single-gene testing with religious and legal constraints on embryo selection for non-medical traits. Clinics there run high monogenic testing volumes relative to aneuploidy work — an inversion of the North American mix that vendors frequently misjudge when sizing the opportunity.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits in the moderate band. The top five suppliers control an estimated 56–60% of the Preimplantation Genetic Testing Market, with a Herfindahl-Hirschman Index in the 950–1,150 range — competitive by antitrust convention, but consolidated enough that pricing discipline holds. Below that tier, dozens of regional laboratories compete almost entirely on turnaround time and local clinician relationships rather than assay differentiation. Vertical integration is the defining strategic move: platform vendors are buying interpretation software, and consumables houses are buying laboratory networks to secure captive volume across the Preimplantation Genetic Testing Market.

| Company | Est. Revenue Share Range | Key Offerings for Preimplantation Genetic Testing Market | Strategic Positioning |
| --- | --- | --- | --- |
| CooperSurgical (CooperGenomics) | ~15–18% | PGT-A/M/SR services, IVF disposables, culture media | Bundled clinic contracts; Cook Medical reproductive assets [14] |
| Illumina, Inc. | ~13–16% | VeriSeq PGS, NovaSeq X, MiSeq reagents | Sequencing platform standard; Tempus AI analytics tie-up [15][19] |
| Thermo Fisher Scientific | ~9–12% | Ion ReproSeq PGT-A, Ion AmpliSeq polyploidy kits | Benchtop NGS for mid-volume laboratories [16] |
| Vitrolife Group (Igenomix) | ~8–11% | Reproductive genetics services, time-lapse systems | Culture-to-analysis continuity across the lab [18] |
| Natera, Inc. | ~6–9% | Spectrum PGT-A, combined single-gene panels | Bioinformatics depth and payer contracting strength [17] |
| Labcorp | ~4–6% | Reference reproductive genetics testing | National logistics and phlebotomy footprint |
| Quest Diagnostics | ~3–5% | Carrier and reproductive genetic panels | Payer network breadth; volume pricing |
| Revvity (formerly PerkinElmer) | ~3–5% | Reproductive health assays and instrumentation | Newborn and prenatal adjacency |
| Yikon Genomics | ~2–4% | NICS non-invasive chromosome screening | China domestic cost leadership |
| Genea Biomedx | ~2–3% | Geri incubation, embryo assessment tools | Asia-Pacific and Australian clinic base |
| Fulgent Genetics | ~1–3% | Reproductive panels with AI-assisted analysis | Flexible panel design; competitive turnaround |
| Agilent Technologies | ~1–3% | aCGH arrays, reagents and quality controls | Legacy array installed base support |

## Recent News & Developments

## Recent News & Developments

- Thermo Fisher Scientific (July 2023): Launched the Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit on Ion Torrent, its first research-use reproductive health assays — extending benchtop sequencing to mid-volume laboratories [[16]](https://ir.thermofisher.com/)
- Orchid Health (January 2024): Introduced the first commercially available whole-genome sequencing service for preimplantation embryos, opening an ethical and regulatory debate that professional societies have yet to resolve [[12]](https://www.asrm.org/)
- m
- Human Reproduction (September 2024): Published multicentre evidence that extended day-six culture protocols raise non-invasive testing informativity without harming embryo viability or live-birth rates [[10]](https://academic.oup.com/humrep/article/39/9/1952/7721576)
- The White House (February 2025): Executive Order 14216 directed policy recommendations to protect IVF access and reduce out-of-pocket and health plan costs, signalling federal intent to expand the covered patient pool [[3]](https://www.govinfo.gov/content/pkg/DCPD-202500278/pdf/DCPD-202500278.pdf)
- Illumina (January 2025): Released NovaSeq X Series upgrades including a single-flow-cell configuration, revised software and improved reagent kits, lowering per-embryo sequencing economics [[15]](https://investor.illumina.com/)

- The White House (October 2025): Announced an EMD Serono agreement cutting typical IVF medication costs by 84% via a federal direct-purchase platform, plus a pathway for employers to offer standalone fertility benefits [[4]](https://www.whitehouse.gov/)

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global preimplantation genetic testing across test type, technology, product and service, application, end user and geography |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 9.8% (2026–2035) |
| Market Size Checkpoints | USD 954.0 Million (2025); USD 1,047.5 Million (2026); USD 1,522.6 Million (2030); USD 2,429.9 Million (2035) |
| Fastest Growing Segments | Non-Invasive PGT (test type); AI-Assisted Imaging (technology); Software and Services (product); Diagnostic Laboratories (end user); Asia-Pacific (geography) |
| Companies Profiled | CooperSurgical, Illumina, Thermo Fisher Scientific, Vitrolife Group, Natera, Labcorp, Quest Diagnostics, Revvity, Yikon Genomics, Genea Biomedx, Fulgent Genetics, Agilent Technologies |
| Valuation Currency | USD Million, constant 2025 prices |

## Frequently Asked Questions

**Q: What should investors evaluate before entering the Preimplantation Genetic Testing Market?**
A: Recurring consumable pull-through matters more than instrument placements. Scrutinise laboratory accreditation depth, payer contract duration, and clinic churn, since losing a single chain account can erase a year of volume growth. [14]

**Q: How should clinics choose between in-house and outsourced testing in the Preimplantation Genetic Testing Market?**
A: In-house sequencing typically pays back above roughly 900 annual biopsies; below that, reference-laboratory contracts cost less. Weigh embryologist retention and bioinformatics licensing, which often exceed instrument depreciation. [13]

**Q: Does mosaicism reporting create liability exposure for laboratories?**
A: Yes. Intermediate copy-number calls fall outside binary euploid classification, and society guidance is advisory rather than statutory. Laboratories increasingly issue tiered reports with documented counselling to limit wrongful-birth claims. [9]

**Q: How does turnaround time affect pricing power?**
A: Clinics running fresh-transfer protocols pay premiums for same-day results. Vendors compressing turnaround below 18 hours command roughly 12–15% higher per-embryo pricing than five-day reference laboratories. [17]

**Q: What integration hurdles slow adoption across the Preimplantation Genetic Testing Market?**
A: Electronic record interoperability is the main bottleneck. Most fertility practice systems lack structured genomic result fields, forcing manual transcription that introduces error and consumes embryologist hours. [20]

**Q: Which emerging use case could reshape demand fastest?**
A: Polygenic embryo scoring. Professional societies have not endorsed it, and ethical scrutiny is intense, yet direct-pay economics are pulling several laboratories toward limited commercial offerings. [12]

**Q: How do cross-border patients influence the Preimplantation Genetic Testing Market?**
A: Restrictive statutes in Germany, Italy and parts of the Gulf push patients toward Spain, Cyprus and the Czech Republic. That flow concentrates preimplantation genetic diagnosis revenue in a handful of high-volume European laboratories. [7]


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/preimplantation-genetic-testing-market-8121*